BeiGene, Ltd.: BeiGene Reports First Quarter 2023 Financial Results and Corporate Developments

Recorded first quarter product revenue of $410.3 million, increasing 56.9% over $261.6 million from the prior-year period Launched BRUKINSA in the U.S. for adult patients with chronic lymphocytic

Related Keywords

Guangzhou ,Guangdong ,China ,Switzerland ,Brazil ,United States ,Australia ,Beijing ,South Korea ,Suzhou ,Jiangsu ,United Kingdom ,Cambridge ,Cambridgeshire ,Japan ,Sao Paulo ,Sãpaulo ,Canada ,America ,Great Britain ,Korea ,American ,Kevin Mannix ,Kyle Blankenship ,Zealand Medsafe ,Johnv Oyler ,Julia Wang ,Health Canada ,Janssen Biotech Inc ,Devices Agency ,Nasdaq ,Bio Thera Solutions Ltd ,Amgen ,Korea Ministry Of Food ,Regulatory Agency ,Exchange Commission ,Beigene Ltd ,National Medical Products Administration ,Novartis ,American Association For Cancer Research ,European Medicines Agency ,European Union ,Development Programs ,Chief Financial Officer ,Product Sales ,American Depositary Share ,Cash Equivalents ,Restricted Cash ,Short Term Investments ,New Drug Application ,Cancer Research ,Chimeric Degradation Activating Compound ,Second Mitochondrial Derived Activator ,Springworks Therapeutics ,Leads Biolabs ,Princeton West Innovation Campus ,New Zealand ,Korea Ministry ,Drug Safety ,Medical Devices Agency ,Biliary Tract Cancer ,Condensed Consolidated Balance Sheet Data ,Consolidated Statements ,American Depositary Shares ,Condensed Consolidated Financial Statements ,Significant Accounting ,Prior Period Financial ,Quarterly Report ,Private Securities Litigation Reform Act ,Latin America ,Bio Thera Solutions ,Janssen Biotech ,Beigene ,Reports ,First ,Quarter ,023 ,Financial ,Results ,Corporate ,Developments ,